 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||||| 11-valent recombinant HPV vaccine / Sinopharm
Enrollment open: A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years (clinicaltrials.gov) - Jun 8, 2022
P3, N=13500, Recruiting, Sponsor: National Vaccine and Serum Institute, China
Not yet recruiting --> Recruiting
- |||| 11-valent recombinant HPV vaccine / Sinopharm
Trial completion: Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) (clinicaltrials.gov) - May 6, 2022
P2, N=480, Completed, Sponsor: National Vaccine and Serum Institute, China
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| 11-valent recombinant HPV vaccine / Sinopharm
New P3 trial: A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years (clinicaltrials.gov) - Mar 2, 2022
P3, N=13500, Not yet recruiting, Sponsor: National Vaccine and Serum Institute, China
- || 11-valent recombinant HPV vaccine / Sinopharm
Trial completion date, Trial primary completion date: Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) (clinicaltrials.gov) - Feb 15, 2022
P2, N=480, Active, not recruiting, Sponsor: National Vaccine and Serum Institute, China
Active, not recruiting --> Completed Trial completion date: Dec 2021 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Mar 2022
- ||| 11-valent recombinant HPV vaccine / Sinopharm
Trial completion: A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years (clinicaltrials.gov) - Nov 24, 2021
P1, N=90, Completed, Sponsor: National Vaccine and Serum Institute, China
Trial completion date: Dec 2021 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Mar 2022 Active, not recruiting --> Completed
- || 11-valent recombinant HPV vaccine / Sinopharm
Trial completion date, Trial primary completion date: Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) (clinicaltrials.gov) - Sep 1, 2021
P2, N=480, Active, not recruiting, Sponsor: National Vaccine and Serum Institute, China
Active, not recruiting --> Completed Trial completion date: Jul 2021 --> Oct 2021 | Trial primary completion date: Jul 2021 --> Oct 2021
- || 11-valent recombinant HPV vaccine / Sinopharm
Trial completion date, Trial primary completion date: A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years (clinicaltrials.gov) - Aug 27, 2021
P1, N=90, Active, not recruiting, Sponsor: National Vaccine and Serum Institute, China
Trial completion date: Jul 2021 --> Oct 2021 | Trial primary completion date: Jul 2021 --> Oct 2021 Trial completion date: Jul 2021 --> Oct 2021 | Trial primary completion date: Jul 2021 --> Oct 2021
- || 11-valent recombinant HPV vaccine / Sinopharm
Trial primary completion date: Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) (clinicaltrials.gov) - Apr 22, 2021
P2, N=480, Active, not recruiting, Sponsor: National Vaccine and Serum Institute, China
Trial completion date: Jul 2021 --> Oct 2021 | Trial primary completion date: Jul 2021 --> Oct 2021 Trial primary completion date: Jan 2021 --> Jul 2021
- || 11-valent recombinant HPV vaccine / Sinopharm
Trial completion date, Trial primary completion date: A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years (clinicaltrials.gov) - Apr 22, 2021
P1, N=90, Active, not recruiting, Sponsor: National Vaccine and Serum Institute, China
Trial primary completion date: Jan 2021 --> Jul 2021 Trial completion date: Mar 2021 --> Jul 2021 | Trial primary completion date: Mar 2021 --> Jul 2021
- || 11-valent recombinant HPV vaccine / Sinopharm
Enrollment closed: A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years (clinicaltrials.gov) - Dec 2, 2020
P1, N=90, Active, not recruiting, Sponsor: National Vaccine and Serum Institute, China
Trial completion date: Mar 2021 --> Jul 2021 | Trial primary completion date: Mar 2021 --> Jul 2021 Recruiting --> Active, not recruiting
- ||| 11-valent recombinant HPV vaccine / Sinopharm
Enrollment closed: Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) (clinicaltrials.gov) - Aug 25, 2020
P2, N=480, Active, not recruiting, Sponsor: National Vaccine and Serum Institute, China
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| 11-valent recombinant HPV vaccine / Sinopharm
New P2 trial: Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) (clinicaltrials.gov) - Jun 16, 2020
P2, N=480, Recruiting, Sponsor: National Vaccine and Serum Institute, China
- | 11-valent recombinant HPV vaccine / Sinopharm
New P1 trial: A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years (clinicaltrials.gov) - Sep 9, 2019
P1, N=90, Recruiting, Sponsor: National Vaccine and Serum Institute, China